TX05 (trastuzumab)

BIOLOGICAL2 trials

Sponsors

Tanvex BioPharma USA, Inc.

Conditions

Breast CancerBreast NeoplasmsEarly-stage Breast CancerHER2-positive Breast CancerStage II Breast CancerStage IIIA Breast Cancer

Phase 3

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

CompletedNCT03556358

Tanvex BioPharma USA, Inc.Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer +2

Start: 2018-06-28End: 2021-02-04Updated: 2022-01-14

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

CompletedNCT04109391

Tanvex BioPharma USA, Inc.Breast Cancer, Breast Neoplasms, Early-stage Breast Cancer +3

Start: 2019-08-20End: 2022-03-08Updated: 2022-10-26

Related Papers

TX05-03e: Adjuvant treatment following neoadjuvant treatment and surgical resection in TX05-03, a trial comparing the safety, efficacy, and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ EBC.

Journal of Clinical Oncology2022-06-08